Definition

Ipamorelin is a pentapeptide (5 amino acids) that acts as a selective growth hormone secretagogue receptor (GHSR) agonist — binding ghrelin receptors in the pituitary to stimulate growth hormone release. Its clinical interest stems from its selectivity: unlike earlier generation GHRPs (GHRP-2, GHRP-6), ipamorelin does not significantly elevate cortisol, prolactin, or ACTH at standard doses, reducing the risk of stimulating unwanted hormonal pathways. It produces pulsatile GH release that closely mimics natural GH secretion patterns. Potential benefits studied include improved body composition, enhanced sleep quality (GH is secreted predominantly during deep sleep), accelerated recovery, and anti-aging effects. Like CJC-1295, it is not FDA-approved for these indications and is subject to evolving regulatory constraints.

Frequently Asked Question

Why Ipamorelin Matters

The most common reason a growth hormone secretagogue might be inappropriate for a midlife woman is cortisol: if she already has elevated cortisol from chronic stress, poor sleep, and HPA axis dysregulation, the last intervention she needs is one that further stimulates cortisol secretion. Ipamorelin's selectivity — stimulating GH without meaningfully elevating cortisol — addresses this directly. For SPOKEmed's patient population, where cortisol dysregulation is nearly universal, this selectivity profile is not a minor pharmacological detail but a clinically important feature that distinguishes ipamorelin from earlier GHRPs in this specific context.

How Spokmed Company Uses It

Ipamorelin may be considered at SPOKEmed as part of individualized longevity and body composition protocols, subject to current regulatory availability and individual patient evaluation.